Cost-effectiveness analysis of pembrolizumab versus targeted therapies in advanced melanoma

Background. The modern therapies of advanced melanoma include targeted medicines for patients with BRAF mutations. Nowadays, a new perspective on immuno-oncologic medicine pembolizumab became available in Russia. Objective. Assessment of the clinical and economic effectiveness of the use of pemboliz...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	E. G. Kosolapov, F. S. Kochenkov, S. K. Zyryanov, O. A. Gladkov
Format:	Artigo
Sprog:	Russo
Udgivet:	Izdatelstvo OKI 2018-05-01
Serier:	Качественная клиническая практика
Fag:	пембролизумаб клинико-экономический анализ фармакоэкономическое исследование вемурафениб дабрафениб онкоиммунология таргетная терапия метастатическая меланома pembrolizumab cost-effectiveness health economics vemurafenib dabrafenib oncoimmunology targeted therapy advanced melanoma
Online adgang:	https://www.clinvest.ru/jour/article/view/83
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!